Ronald B Goldberg

Summary

Affiliation: University of Miami
Country: USA

Publications

  1. pmc Improving glycemic and cholesterol control through an integrated approach incorporating colesevelam - a clinical perspective
    Ronald B Goldberg
    Division of Endocrinology, Diabetes and Metabolism, Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL, USA
    Diabetes Metab Syndr Obes 2:11-21. 2009
  2. doi request reprint Colesevelam improved lipoprotein particle subclasses in patients with prediabetes and primary hyperlipidaemia
    Ronald B Goldberg
    Division of Endocrinology, Diabetes and Metabolism, University of Miami Miller School of Medicine, Miami, FL 33136, USA
    Diab Vasc Dis Res 10:256-62. 2013
  3. doi request reprint Initial combination therapy with metformin plus colesevelam improves lipoprotein particles in patients with early type 2 diabetes mellitus
    Ronald B Goldberg
    Division of Endocrinology, Diabetes and Metabolism, University of Miami Miller School of Medicine, Miami, FL 33136, USA
    J Clin Lipidol 6:318-24. 2012
  4. pmc Targeting the consequences of the metabolic syndrome in the Diabetes Prevention Program
    Ronald B Goldberg
    Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA
    Arterioscler Thromb Vasc Biol 32:2077-90. 2012
  5. doi request reprint Effects of niacin on glucose control in patients with dyslipidemia
    Ronald B Goldberg
    Lipid Disorders Clinic, Division of Endocrinology, Diabetes, and Metabolism, University of Miami Leonard M Miller School of Medicine, 1450 NW 10th Ave, Miami, FL 33136, USA
    Mayo Clin Proc 83:470-8. 2008
  6. ncbi request reprint Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study
    Ronald B Goldberg
    Diabetes Research Institute, Miller School of Medicine, University of Miami, 1450 NW 10th Ave, Miami, FL 33136, USA
    Mayo Clin Proc 81:1579-88. 2006
  7. ncbi request reprint The new clinical trials with thiazolidinediones--DREAM, ADOPT, and CHICAGO: promises fulfilled?
    Ronald B Goldberg
    Division of Endocrinology, Diabetes and Metabolism, Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    Curr Opin Lipidol 18:435-42. 2007
  8. ncbi request reprint Thiazolidinediones and vascular damage
    Ronald B Goldberg
    Division of Endocrinology, Diabetes and Metabolism, Diabetes Research Institute, The University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    Curr Opin Endocrinol Diabetes Obes 14:108-15. 2007
  9. pmc Relationships between metabolic syndrome and other baseline factors and the efficacy of ezetimibe/simvastatin and atorvastatin in patients with type 2 diabetes and hypercholesterolemia
    Ronald B Goldberg
    University of Miami Miller School of Medicine, Miami, Florida, USA
    Diabetes Care 33:1021-4. 2010
  10. ncbi request reprint Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy
    Ronald B Goldberg
    Lipid Disorders Clinic, Division of Endocrinology Diabetes and Metabolism, and Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA
    Arch Intern Med 168:1531-40. 2008

Research Grants

Detail Information

Publications43

  1. pmc Improving glycemic and cholesterol control through an integrated approach incorporating colesevelam - a clinical perspective
    Ronald B Goldberg
    Division of Endocrinology, Diabetes and Metabolism, Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL, USA
    Diabetes Metab Syndr Obes 2:11-21. 2009
    ..Colesevelam thus combines antihyperglycemic action with LDL-C-lowering properties, and should be useful in the management of type 2 diabetes...
  2. doi request reprint Colesevelam improved lipoprotein particle subclasses in patients with prediabetes and primary hyperlipidaemia
    Ronald B Goldberg
    Division of Endocrinology, Diabetes and Metabolism, University of Miami Miller School of Medicine, Miami, FL 33136, USA
    Diab Vasc Dis Res 10:256-62. 2013
    ..We report the effect of colesevelam on lipoprotein particle concentration and particle size (determined by nuclear magnetic resonance spectroscopy) in these patients...
  3. doi request reprint Initial combination therapy with metformin plus colesevelam improves lipoprotein particles in patients with early type 2 diabetes mellitus
    Ronald B Goldberg
    Division of Endocrinology, Diabetes and Metabolism, University of Miami Miller School of Medicine, Miami, FL 33136, USA
    J Clin Lipidol 6:318-24. 2012
    ..The bile acid sequestrant colesevelam has been shown to significantly reduce low-density lipoprotein particle concentration (LDL-P) in adults with primary hyperlipidemia or type 2 diabetes mellitus (T2DM)...
  4. pmc Targeting the consequences of the metabolic syndrome in the Diabetes Prevention Program
    Ronald B Goldberg
    Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA
    Arterioscler Thromb Vasc Biol 32:2077-90. 2012
    ..Thus a program of lifestyle change significantly reduced type 2 diabetes incidence and metabolic syndrome prevalence in subjects at high risk for type 2 diabetes. Metformin had more modest effects...
  5. doi request reprint Effects of niacin on glucose control in patients with dyslipidemia
    Ronald B Goldberg
    Lipid Disorders Clinic, Division of Endocrinology, Diabetes, and Metabolism, University of Miami Leonard M Miller School of Medicine, 1450 NW 10th Ave, Miami, FL 33136, USA
    Mayo Clin Proc 83:470-8. 2008
    ..Consensus guidelines recommend monitoring glycemic control after initiating niacin treatment or increasing its dosage...
  6. ncbi request reprint Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study
    Ronald B Goldberg
    Diabetes Research Institute, Miller School of Medicine, University of Miami, 1450 NW 10th Ave, Miami, FL 33136, USA
    Mayo Clin Proc 81:1579-88. 2006
    ..To compare the efficacy and safety of the recommended usual starting and next highest doses of ezetimibe/ simvastatin and atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia...
  7. ncbi request reprint The new clinical trials with thiazolidinediones--DREAM, ADOPT, and CHICAGO: promises fulfilled?
    Ronald B Goldberg
    Division of Endocrinology, Diabetes and Metabolism, Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    Curr Opin Lipidol 18:435-42. 2007
    ..Three new controlled clinical trials of thiazolidinediones offer new information on the clinical utility of these agents...
  8. ncbi request reprint Thiazolidinediones and vascular damage
    Ronald B Goldberg
    Division of Endocrinology, Diabetes and Metabolism, Diabetes Research Institute, The University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    Curr Opin Endocrinol Diabetes Obes 14:108-15. 2007
    ....
  9. pmc Relationships between metabolic syndrome and other baseline factors and the efficacy of ezetimibe/simvastatin and atorvastatin in patients with type 2 diabetes and hypercholesterolemia
    Ronald B Goldberg
    University of Miami Miller School of Medicine, Miami, Florida, USA
    Diabetes Care 33:1021-4. 2010
    ..To investigate relationships between baseline factors and treatment-associated efficacy changes in type 2 diabetes...
  10. ncbi request reprint Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy
    Ronald B Goldberg
    Lipid Disorders Clinic, Division of Endocrinology Diabetes and Metabolism, and Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA
    Arch Intern Med 168:1531-40. 2008
    ..Poor glycemic control is a risk factor for microvascular complications in patients with type 2 diabetes mellitus. Achieving glycemic control safely with insulin therapy can be challenging...
  11. ncbi request reprint Lifestyle interventions to prevent type 2 diabetes
    Ronald B Goldberg
    Diabetes Research Institute, Miller School of Medicine, University of Miami, Miami, FL 33136, USA
    Lancet 368:1634-6. 2006
  12. ncbi request reprint Impact of thiazolidenediones on serum lipoprotein levels
    Ronald B Goldberg
    Division of Endocrinology, Diabetes and Metabolism, University of Miami Miller School of Medicine, 1450 NW 10th Avenue, Miami, FL 33136, USA
    Curr Atheroscler Rep 8:397-404. 2006
    ..The clinical implications of these effects need further exploration...
  13. ncbi request reprint Cardiovascular disease in patients who have diabetes
    Ronald B Goldberg
    Division of Endocrinology, Diabetes, and Metabolism, Diabetes Research Institute, University of Miami School of Medicine, 1450 NW 10th Avenue R77, Miami, FL 33136, USA
    Cardiol Clin 21:399-413, vii. 2003
    ..In addition, newer agents and early intervention in prediabetic and diabetic individuals hold promise for even greater success in the prevention of this important complication of diabetes...
  14. ncbi request reprint Fish oil in the treatment of dyslipidemia
    Ronald B Goldberg
    Division of Endocrinology and Metabolism, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    Curr Opin Endocrinol Diabetes Obes 15:167-74. 2008
    ..This review examines the evidence supporting the use of omega-3 fatty acid treatment in dyslipidemic states...
  15. ncbi request reprint Is the factor structure of the metabolic syndrome comparable between men and women and across three ethnic groups: the Miami Community Health Study
    Biing Jiun Shen
    Department of Psychology, University of Miami, Coral Gables, FL 33124 0751, USA
    Ann Epidemiol 16:131-7. 2006
    ..This study uses confirmatory factor analysis to evaluate the factor structure of the MS and examines its similarity between men and women and across three ethnic groups (Caucasian, African, and Cuban Americans)...
  16. doi request reprint Central obesity and insulin resistance in the cardiometabolic syndrome: pathways to preclinical cardiovascular structure and function
    Johanna R Klaus
    Behavioral Medicine Research Center, University of Miami, Miami, FL 33136, USA
    J Cardiometab Syndr 4:63-71. 2009
    ..The findings suggest predominant pathways through which subclinical metabolic processes may exert pathogenic impact on the heart and vasculature...
  17. pmc Genetic modulation of lipid profiles following lifestyle modification or metformin treatment: the Diabetes Prevention Program
    Toni I Pollin
    Division of Endocrinology, Diabetes, and Nutrition, Department of Medicine, and Program in Genetics and Genomic Medicine, University of Maryland School of Medicine, Baltimore, Maryland, United States of America
    PLoS Genet 8:e1002895. 2012
    ..Our findings suggest that a high genetic burden confers an adverse lipid profile and predicts attenuated response in LDL-C levels and small LDL particle number to dietary and physical activity interventions aimed at weight loss...
  18. pmc Impact of lifestyle intervention and metformin on health-related quality of life: the diabetes prevention program randomized trial
    Hermes Florez
    University of Miami, Coral Gables, USA
    J Gen Intern Med 27:1594-601. 2012
    ..Adults at high risk for diabetes may have reduced health-related quality of life (HRQoL)...
  19. ncbi request reprint A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia
    Ronald B Goldberg
    Division of Endocrinology, Metabolism and Diabetes, University of Miami School of Medicine, Miami, Florida, USA
    Diabetes Care 28:1547-54. 2005
    ..This study examines the lipid and glycemic effects of pioglitazone and rosiglitazone...
  20. doi request reprint Clinical decisions. Management of type 2 diabetes
    Ronald B Goldberg
    Division of Endocrinology, Diabetes, and Metabolism, Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, USA
    N Engl J Med 358:293-7. 2008
  21. ncbi request reprint Management of dyslipidemia in diabetes
    Maria P Solano
    University of Miami School of Medicine, Miami, Florida, USA
    Cardiol Rev 14:125-35. 2006
    ..Statin therapy is recommended for most subjects but, frequently, a combination of lipid-lowering agents is required. A number of combinations are possible, and several factors should be considered to improve the safety of this strategy...
  22. doi request reprint Long-term oral contraceptive treatment, metabolic syndrome and measures of cardiovascular risk in pre-menopausal women: National Health and Nutrition Examination Survey 1999-2004
    Barry E Hurwitz
    Behavioral Medicine Research Centre, University of Miami, Clinical Research Building 777, 1120 NW 14th Street, Miami, FL 33136, USA
    Gynecol Endocrinol 25:441-9. 2009
    ..Differences in subclinical cardiometabolic measures were examined as a function of oral contraceptive pills (OCP) treatment duration to compare never-treated women with four OCP-treatment groups (<1, 1-5, 5-10 and >10 years)...
  23. ncbi request reprint Effect of ezetimibe/simvastatin vs atorvastatin on lowering levels of LDL-C and non-HDL-C, ApoB, and hs-CRP in patients with type 2 diabetes
    Ruth S Weinstock
    Division of Endocrinology, Diabetes and Metabolism, SUNY Upstate Medical University and VA Medical Center, 750 E Adams Street, CWB 353, Syracuse, NY 13210, USA
    J Clin Lipidol 2:25-35. 2008
    ....
  24. ncbi request reprint Lipoprotein and apolipoprotein ratios in the VYTAL trial of ezetimibe/simvastatin compared with atorvastatin in type 2 diabetes
    John R Guyton
    Department of Medicine, Division of Endocrinology, Metabolism and Nutrition, Box 3510, Duke University, Durham, NC 27710, USA
    J Clin Lipidol 2:19-24. 2008
    ....
  25. ncbi request reprint Management of diabetic dyslipidemia
    Maria Del Pilar Solano
    Division of Diabetes, Endocrinology, and Metabolism, Diabetes Research Institute, University of Miami, Miami, FL 33136, USA
    Endocrinol Metab Clin North Am 34:1-25, v. 2005
    ..Although statin therapy is recommended for most subjects, judicious use of combination therapy should be considered in the highest risk subjects...
  26. pmc Triglyceride response to an intensive lifestyle intervention is enhanced in carriers of the GCKR Pro446Leu polymorphism
    Toni I Pollin
    Division of Endocrinology, Diabetes, and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland21201, USA
    J Clin Endocrinol Metab 96:E1142-7. 2011
    ..OBJECTIVE, SETTING, AND PATIENTS: We sought to replicate these associations and evaluate interactions with lifestyle and metformin interventions in the multiethnic Diabetes Prevention Program (DPP)...
  27. ncbi request reprint Ability of serum to decrease cellular acylCoA:cholesterol acyl transferase activity predicts cardiovascular outcomes
    Julio A Chirinos
    Miller School of Medicine, University of Miami, Miami, FL 33138, USA
    Circulation 112:2446-53. 2005
    ..We evaluated whether cholesterol efflux activity of serum is associated with the presence of angiographic coronary artery disease (CAD) and the risk of major adverse cardiovascular events (MACE) and death...
  28. ncbi request reprint Effect of behavioral interventions on insulin sensitivity and atherosclerosis in the Watanabe heritable hyperlipidemic rabbit
    Julie A Gonzales
    Department of Psychology, University of Miami, Coral Gables, FL 33124, USA
    Psychosom Med 67:172-8. 2005
    ....
  29. pmc Insulin resistance and risk of ischemic stroke among nondiabetic individuals from the northern Manhattan study
    Tatjana Rundek
    Department of Neurology, Miller School of Medicine, University of Miami, Miami, FL 33136, USA
    Arch Neurol 67:1195-200. 2010
    ..Whether insulin resistance predicts ischemic stroke (IS) is still a matter of debate...
  30. ncbi request reprint Sensory function and albumin excretion according to diagnostic criteria for diabetes
    Jay M Sosenko
    Department of Medicine, University of Miami School of Medicine, Miami, FL 33101, USA
    Diabetes Care 27:1716-20. 2004
    ..The purpose of this study was to examine sensory function and albumin excretion according to categories of glucose tolerance in individuals undergoing screening for diabetes...
  31. doi request reprint Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications
    Ronald B Goldberg
    Division of Endocrinology, Diabetes, and Metabolism, Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, Florida 33101, USA
    J Clin Endocrinol Metab 94:3171-82. 2009
    ..Their circulating biomarkers may therefore provide opportunities for early diagnosis and targets for novel treatments...
  32. pmc Type 2 diabetes mellitus among Florida children and adolescents, 1994 through 1998
    Christine J Macaluso
    University of South Florida, Tampa, FL, USA
    Public Health Rep 117:373-9. 2002
    ..This study was undertaken to examine the trends in the diagnosis of Type 2 diabetes mellitus among children and adolescents with new-onset diabetes seen from 1994 through 1998 at the three university-based diabetes centers in Florida...
  33. ncbi request reprint Severe acquired (secondary) high-density lipoprotein deficiency
    Ronald B Goldberg
    Lipid Disorders Clinic, Division of Endocrinology Diabetes and Metabolism, Diabetes Research Institute, University of Miami Miller School of Medicine, 1450 N W 10th Avenue, Miami, FL 33136, USA
    J Clin Lipidol 1:41-56. 2007
    ..Case discussions from our clinical experience are provided to illustrate to the practitioner the clinical context in which these severe acquired deficiencies of HDL occur...
  34. ncbi request reprint Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia
    Mark A Deeg
    Department of Endocrinology and Metabolism, Veterans Affairs Hospital and Indiana University, Indianapolis, Indiana, USA
    Diabetes Care 30:2458-64. 2007
    ..We studied the effects of pioglitazone (PIO) and rosiglitazone (ROSI) treatments on serum lipoprotein particle concentrations and sizes in type 2 diabetic patients with dyslipidemia...
  35. pmc Extension of type 2 diabetes genome-wide association scan results in the diabetes prevention program
    Allan F Moore
    Center for Human Genetic Research, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
    Diabetes 57:2503-10. 2008
    ....
  36. doi request reprint Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation
    John D Brunzell
    Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, and the Northwest Lipid Laboratory, University of Washington, Seattle, Washington, USA
    Diabetes Care 31:811-22. 2008
  37. doi request reprint Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center Inc, 3288 Illinois Ave, Louisville, KY 40213, USA
    Arch Intern Med 168:1975-83. 2008
    ..Bile acid sequestrants are a well-accepted class of cholesterol-lowering drugs. Over the last decade, small studies have indicated that these agents may also lower glucose levels in patients with type 2 diabetes mellitus (T2DM)...
  38. ncbi request reprint Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, rand
    David C Robbins
    Diabetes and Endocrine Platform Team, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Clin Ther 29:2349-64. 2007
    ..Using lispro mix (LM) 50/50 before meals may be a logical approach to achieving glycemic targets (glycosylated hemoglobin [HbA(lc)] and pre- and postprandial blood glucose [BG] concentrations) in these patients...
  39. ncbi request reprint The 'forgotten' bile acid sequestrants: is now a good time to remember?
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY 40213, USA
    Am J Ther 14:567-80. 2007
    ....
  40. ncbi request reprint Lifestyle intervention to prevent diabetes: intensive and cost effective
    Judith Wylie-Rosett
    Division of Health Behavior and Nutrition, Department of Epidemiology and Population Health, Albert Einstein College of Medicine, New York, New York, USA
    Curr Opin Lipidol 17:37-44. 2006
    ..Recent clinical trials have now tested the effectiveness of this intervention and form the basis for this review...
  41. ncbi request reprint New strategies for the treatment of diabetic dyslipidemia
    Steven M Haffner
    Diabetes Care 25:1237-9. 2002
  42. ncbi request reprint Prevalence of the metabolic syndrome in Peruvian Andean hispanics: the PREVENCION study
    Josefina Medina-Lezama
    Santa Maria Catholic University School of Medicine and Santa Maria Research Institute, Arequipa, Peru
    Diabetes Res Clin Pract 78:270-81. 2007
    ..Further studies are required to characterize genetic and environmental determinants of these patterns...
  43. doi request reprint Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation
    John D Brunzell
    Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, Northwest Lipid Laboratory, University of Washington, Seattle, Washington, USA
    J Am Coll Cardiol 51:1512-24. 2008

Research Grants5

  1. Post Diabetes Prevention Program Follow-up Study
    Ronald Goldberg; Fiscal Year: 2007
    ..women, and in older subjects in the DPP. The current application is for 5 years of funding, although the some of the goals of the projects described will require a 10-year study. ..
  2. Biomarkers and Outcomes in the Diabetes Prevention Program
    Ronald Goldberg; Fiscal Year: 2009
    ....
  3. Biomarkers and Outcomes in the Diabetes Prevention Program
    Ronald B Goldberg; Fiscal Year: 2010
    ....